The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists

Advances in the physiology of gastric emptying

(2019) Raj K. Goyal et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?

(2018) Raffaella Gentilella et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

Gastrointestinal hormones and regulation of gastric emptying

(2018) Michael Camilleri   Current Opinion in Endocrinology Diabetes and Obesity

A Novel Humanized GLP-1 Receptor Model Enables Both Affinity Purification and Cre-LoxP Deletion of the Receptor

(2014) Lucy S. Jun et al.   PLoS One

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia

(2013) M. M. Umapathysivam et al.   DIABETES

Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight

(2012) J. Jelsing et al.   DIABETES OBESITY & METABOLISM

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

(2011) M. A. Nauck et al.   DIABETES

Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis

(2010) T. Edholm et al.   NEUROGASTROENTEROLOGY AND MOTILITY